Compare KYMR & EHC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KYMR | EHC |
|---|---|---|
| Founded | 2015 | 1983 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Hospital/Nursing Management |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6B | 11.2B |
| IPO Year | 2020 | 1994 |
| Metric | KYMR | EHC |
|---|---|---|
| Price | $121.83 | $122.72 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 26 | 7 |
| Target Price | $107.72 | ★ $143.29 |
| AVG Volume (30 Days) | 613.0K | ★ 874.4K |
| Earning Date | 04-30-2026 | 04-30-2026 |
| Dividend Yield | N/A | ★ 0.74% |
| EPS Growth | N/A | ★ 24.22 |
| EPS | N/A | ★ 3.47 |
| Revenue | ★ $39,211,000.00 | N/A |
| Revenue This Year | $10.61 | $9.33 |
| Revenue Next Year | $8.17 | $8.14 |
| P/E Ratio | ★ N/A | $35.16 |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $39.84 | $92.77 |
| 52 Week High | $130.05 | $127.99 |
| Indicator | KYMR | EHC |
|---|---|---|
| Relative Strength Index (RSI) | 67.81 | 65.50 |
| Support Level | $76.40 | $106.68 |
| Resistance Level | $130.05 | $127.50 |
| Average True Range (ATR) | 4.22 | 2.93 |
| MACD | 1.29 | 0.25 |
| Stochastic Oscillator | 91.57 | 78.06 |
Kymera Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to reinventing the treatment of human disease through the development of differentiated medicines that address health problems and meaningfully improve patients' lives. It is committed to novel technologies to address targets that have known disease-causing biology, but which have not been drugged, or have been inadequately drugged, often based on limitations of existing technologies. Its approach is intended to discover and develop a new generation of medicines in a disease-agnostic manner. Its product pipelines are STAT6, and IRAK4.
Encompass Health Corp provides post-acute healthcare services in the United States through a network of inpatient rehabilitation hospitals, which is the company's sole segment. Inpatient rehabilitation contributes the majority of the firm's revenue and provides specialized rehabilitative treatment through a network of inpatient hospitals. The company's inpatient rehabilitation hospitals provide a higher level of rehabilitative care to patients who are recovering from conditions such as stroke and other neurological disorders, cardiac and pulmonary conditions, brain and spinal cord injuries, complex orthopedic conditions, and amputations.